Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.
